Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.84 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.84 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.84 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.84 |
| ▸ | PDE2A | O00408 | 1/20 | 0.84 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.84 |
| ▸ | PDE6D | O43924 | 1/20 | 0.84 |
| ▸ | PDE8A | O60658 | 1/20 | 0.84 |
| ▸ | PDE9A | O76083 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.84 |
| ▸ | HTR1A | P08908 | 1/20 | 0.84 |
| ▸ | PDE6A | P16499 | 1/20 | 0.84 |
| ▸ | PDE6G | P18545 | 1/20 | 0.84 |
| ▸ | PDE4A | P27815 | 1/20 | 0.84 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.84 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.84 |
| ▸ | PDE6B | P35913 | 1/20 | 0.84 |
| ▸ | PDE6C | P51160 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sildenafil SCHEMBL1895 | 0.91 | PDE5A (1.00) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL5683880 | 0.91 | PDE5A (1.00) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL29361663 | 0.91 | PDE5A (1.00) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL584340 | 0.91 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL7915871 | 0.91 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL6689399 | 0.91 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL19410952 | 0.91 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL5691322 | 0.91 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| Sildenafil SCHEMBL1801562 | 0.91 | PDE5A (0.98) | PDE5APDE3BPDE3AABCC4PDE2A | |
| SCHEMBL28417921 | 0.91 | PDE5A (0.89) | PDE5APDE3BPDE3AABCC4PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716298-B2 | Composition for reducing skin wrinkles including PDE5 inhibitor | SK CHEMICALS CO., LTD. (KR) | 2014-05-06 | — | — | US | claimed |
| EP-2556820-A2 | COMPOSITION CONTAINING PDE5 INHIBITOR FOR RELIEVING SKIN WRINKLES | SK Chemicals, Co., Ltd. (KR) | 2013-02-13 | — | — | EP | claimed |
| US-20130030174-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2013-01-31 | — | — | US | claimed |
| US-20060014754-A1 | Methods and compositions for treating diseases and conditions of the eye | PFIZER INC. | 2006-01-19 | — | — | US | claimed |
| US-20030144296-A1 | Daily treatment for erectile dysfunction using a PDE5 inhibitor | LILLY ICOS LLC | 2003-07-31 | — | — | US | claimed |
| US-20030055070-A1 | Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction | HARRISON WILMA (US) | 2003-03-20 | — | — | US | claimed |
| US-20030027824-A1 | Pyrazolopyrimidinones for the treatment of female sexual dysfunction | ELLIS PETER (GB) | 2003-02-06 | — | — | US | claimed |
| US-6492371-B2 | ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND THAT INHIBITS CGMP-SPECIFIC PHOSPHODIESTERASE (PDE5) FOR THERAPY OF PARKINSON'S DISEASE | ROYLANCE H H (US) | 2002-12-10 | — | — | US | claimed |
| US-6469012-B1 | POTENT, SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASES LEAD TO ELEVATED CGMP LEVELS | PFIZER INC | 2002-10-22 | — | — | US | claimed |
| US-6469016-B1 | VAGINAL, VULVAR AND/OR URETHRAL ADMINISTRATION OF A PHARMACEUTICAL FORMULATION CONTAINING A VASOACTIVE AGENT TO INCREASE VAGINAL LUBRICATION | VIVUS, INC. | 2002-10-22 | — | — | US | claimed |
| US-20020119974-A1 | Methods and compositions for treating diseases and conditions of the eye | LATIES ALAN M (US) | 2002-08-29 | — | — | US | claimed |
| US-20010053780-A1 | Daily treatment for erectile dysfunction using a PDE5 inhibitor | LILLY ICOS LLC, A DELAWARE CORPORATION | 2001-12-20 | — | — | US | claimed |
| US-6225315-B1 | ADMINISTERING A CGMP PDE INHIBITOR. | PFIZER INC | 2001-05-01 | — | — | US | claimed |
| EP-1074258-A2 | Methods and compositions for treating diseases and conditions of the eye | Pfizer Products Inc. (US) | 2001-02-07 | — | — | EP | claimed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | claimed |
| EP-0702555-B1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE | PFIZER LTD (GB) | 1998-03-11 | — | — | EP | claimed |
| EP-0463756-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1995-04-19 | — | — | EP | claimed |
| US-5250534-A | Inhibitors of cyclic guanosine 3*,5*-monophosphate phosphodiesterase | PFIZER INC. (US) | 1993-10-05 | — | — | US | claimed |
| EP-0463756-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1992-01-02 | — | — | EP | claimed |
| US-9943398-B2 | Increasing survival of free tissue grafts and flaps using phosphodiesterase type 5 (PDE5) inhibitors | NEW YORK UNIVERSITY (US) | 2018-04-17 | — | — | US | disclosed |
| US-9155691-B2 | Composition for reducing skin wrinkles including PDE5 inhibitor | SK CHEMICALS CO., LTD. (KR) | 2015-10-13 | — | — | US | disclosed |
| US-20150250791-A1 | COMBINING SILDENAFIL WITH CAFFEINE IN AN ORAL DISINTEGRATING DOSAGE FORM | FORMUREX, INC. | 2015-09-10 | — | — | US | disclosed |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | disclosed |
| US-20140179701-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2014-06-26 | — | — | US | disclosed |
| US-20140128405-A1 | Composition and use for phosphodiesterase inhibitors | CHERVINSKY ALEX (US) | 2014-05-08 | — | — | US | disclosed |
| US-8716298-B2 | Composition for reducing skin wrinkles including PDE5 inhibitor | SK CHEMICALS CO., LTD. (KR) | 2014-05-06 | — | — | US | disclosed |
| US-20140018936-A1 | INCREASING SURVIVAL OF FREE TISSUE GRAFTS AND FLAPS USING PHOSPHODIESTERASE TYPE 5 (PDE5) INHIBITORS | NEW YORK UNIVERSITY (US) | 2014-01-16 | — | — | US | disclosed |
| EP-2556820-A2 | COMPOSITION CONTAINING PDE5 INHIBITOR FOR RELIEVING SKIN WRINKLES | SK Chemicals, Co., Ltd. (KR) | 2013-02-13 | — | — | EP | disclosed |
| US-20130030174-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2013-01-31 | — | — | US | disclosed |
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ASTELLAS PHARMA INC. (JP) | 2012-11-08 | — | — | US | disclosed |
| US-20120245134-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | DUDLEY ROBERT E (US) | 2012-09-27 | — | — | US | disclosed |
| US-8263555-B2 | Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma | ALCON RESEARCH, LTD. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8252793-B2 | Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma | ALCON RESEARCH, LTD. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120157467-A1 | COMPOSITION AND USE FOR PHOSPHODIESTERASE INHIBITORS | CHERVINSKY ALEX (US) | 2012-06-21 | — | — | US | disclosed |
| US-8173668-B1 | Use of non-peptidic bradykinin receptor agonists to treat ocular hypertension and glaucoma | ALCON RESEARCH, LTD. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20120065180-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | DUDLEY ROBERT E (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120058981-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | DUDLEY ROBERT E (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120046285-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20120009152-A1 | NITRIC OXIDE DONORS FOR TREATMENT OF DISEASE AND INJURY | NIH - DEITR | 2012-01-12 | — | — | US | disclosed |
| US-20110306582-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | DUDLEY ROBERT E (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110009322-A1 | USE OF BRADYKININ AND RELATED B2R AGONISTS TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | ALCON RESEARCH, LTD. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7807629-B1 | Use of bradykinin and related B2R agonists to treat ocular hypertension and glaucoma | ALCON RESEARCH, LTD. (US) | 2010-10-05 | — | — | US | disclosed |
| EP-2218442-A1 | Methods, compositions, and kits for the treatment of ophthalmic disorders | CombinatoRx, Inc. (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-1315502-B1 | METHOD FOR TREATING ERECTILE DYSFUNCTION AND INCREASING LIBIDO IN MEN | UNIMED PHARMACEUTICALS LLC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090318398-A1 | ANDROGEN PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING DEPRESSION | UNIMED PHARMACEUTICALS, LLC. (US) | 2009-12-24 | — | — | US | disclosed |
| EP-1956906-A2 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MEDICAL CONDITIONS | CombinatoRx, Incorporated (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070225217-A1 | Methods, compositions, and kits for the treatment of medical conditions | COMBINATORX, INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070197560-A1 | cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction | NAEF RETO | 2007-08-23 | — | — | US | disclosed |
| US-20070154533-A1 | Method of increasing testosterone and related steriod concentrations in women | UNIMED PHARMACEUTICALS, LLC | 2007-07-05 | — | — | US | disclosed |
| WO-2007056457-A2 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF MEDICAL CONDITIONS | COMBINATORX, INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1123088-B1 | SUSTAINED-RELEASE PHARMACEUTICAL FORMULATIONS CONTAINING A CGMP PDE-5 INHIBITOR | PFIZER IRELAND PHARMACEUTICALS (IE) | 2006-09-27 | — | — | EP | disclosed |
| US-20060211664-A1 | Method for treating erectile dysfunction and increasing libido in men | LABORATOIRES BESINS INTERNATIONAL, SAS (FR) | 2006-09-21 | — | — | US | disclosed |
| US-20060040935-A1 | Method of treating impotence due to spinal cord injury | PFIZER INC | 2006-02-23 | — | — | US | disclosed |
| US-20060014754-A1 | Methods and compositions for treating diseases and conditions of the eye | PFIZER INC. | 2006-01-19 | — | — | US | disclosed |
| US-6964780-B1 | Controlled-release pharmaceutical formulations | PFIZER INC. (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1562602-A2 | IMMEDIATE RELEASE TOPICAL PHARMACEUTICAL FORMULATION FOR ENHANCEMENT OF FEMALE SEXUAL DESIRE AND RESPONSIVENESS | Vivus, Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050143388-A1 | Nitric oxide donors for treatment of disease and injury | NIH - DEITR | 2005-06-30 | — | — | US | disclosed |
| US-20050118242-A1 | Androgen pharmaceutical composition and method for treating depression | LABORATORIES BESINS INTERNATIONAL, SAS (FR) | 2005-06-02 | — | — | US | disclosed |
| US-20050054623-A1 | Method for treating erectile dysfunction and increasing libido in men | UNIMED PHARMACEUTICALS, LLC | 2005-03-10 | — | — | US | disclosed |
| US-20050049233-A1 | Method for treating erectile dysfunction and increasing libido in men | LABORATOIRES BESINS INTERNATIONAL, SAS (FR) | 2005-03-03 | — | — | US | disclosed |
| EP-1248623-B1 | TREATMENT OF DIABETIC ULCERS | PFIZER LTD (GB) | 2004-12-29 | — | — | EP | disclosed |
| US-20040214831-A1 | cGMP PDE 5 inhibitors for inhalation in the treatment of sexual dysfunction | NAEF RETO | 2004-10-28 | — | — | US | disclosed |
| EP-1469852-A2 | NITRIC OXIDE DONORS FOR TREATMENT OF DISEASE AND INJURY | HENRY FORD HEALTH SYSTEM (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-0951908-B1 | Treatment of impotence due to spinal cord injury | PFIZER LTD (GB) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004037262-A2 | IMMEDIATE RELEASE TOPICAL PHARMACEUTICAL FORMULATION FOR ENHANCEMENT OF FEMALE SEXUAL DESIRE AND RESPONSIVENESS | VIVUS, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2003056899-A9 | NITRIC OXIDE DONORS FOR TREATMENT OF DISEASE AND INJURY | FORD HENRY HEALTH SYSTEM (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20040014761-A1 | Treatment of female sexual dysfunction with phosphodiesterase inhibitors | VIVUS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20040002482-A1 | Androgen pharmaceutical composition and method for treating depression | UNIMED PHARMACEUTICALS, LLC | 2004-01-01 | — | — | US | disclosed |
| US-20030207852-A1 | Treatment of female sexual dysfunction | PLACE VIRGIL A (US) | 2003-11-06 | — | — | US | disclosed |
| US-20030176442-A1 | Treatment of diabetic ulcers | WOOD RALPH E (US) | 2003-09-18 | — | — | US | disclosed |
| US-20030166661-A1 | L-arginine and phosphodiesterase (PDE) inhibitor synergism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-09-04 | — | — | US | disclosed |
| US-20030144296-A1 | Daily treatment for erectile dysfunction using a PDE5 inhibitor | LILLY ICOS LLC | 2003-07-31 | — | — | US | disclosed |
| US-20030139384-A1 | Method for treating erectile dysfunction and increasing libido in men | LABORATOIRES BESINS INTERNATIONAL, SAS (FR) | 2003-07-24 | — | — | US | disclosed |
| US-20030134861-A1 | Transmucosal phosphodiesterase inhibitors for the treatment of erectile dysfunction | DOHERTY PAUL C (US) | 2003-07-17 | — | — | US | disclosed |
| WO-2003056899-A2 | NITRIC OXIDE DONORS FOR TREATMENT OF DISEASE AND INJURY | HENRY FORD HEALTH SYSTEM (US) | 2003-07-17 | — | — | WO | disclosed |
| US-6593313-B2 | Administering to the vagina, vulvar area or urethra of the female a pharmaceutical formulation comprises a vasoactive agent selected from natural or synthetic prostaglandins, endothelial derived relaxation factors, hypotensive agents | VIVUS, INC. | 2003-07-15 | — | — | US | disclosed |
| EP-1313478-A2 | METHOD FOR TREATMENT OF MIGRAINE USING PDE5 INHIBITORS | Lilly Icos LLC (US) | 2003-05-28 | — | — | EP | disclosed |
| US-6548490-B1 | Transmucosally administering to the individual suffering with erectile dysfunction an effective amount of a phosphodiesterase inhibitor selected from type III or type iv phosphodiesterase inhibitor or both | VIVUS, INC. | 2003-04-15 | — | — | US | disclosed |
| US-20030055070-A1 | Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction | HARRISON WILMA (US) | 2003-03-20 | — | — | US | disclosed |
| US-20030027824-A1 | Pyrazolopyrimidinones for the treatment of female sexual dysfunction | ELLIS PETER (GB) | 2003-02-06 | — | — | US | disclosed |
| US-20030027804-A1 | Therapeutic combinations for the treatment of hormone deficiencies | SOLVAY PHARMACEUTICALS, INC. | 2003-02-06 | — | — | US | disclosed |
| EP-1278522-A2 | PDE-V INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE | Lilly Icos LLC (US) | 2003-01-29 | — | — | EP | disclosed |
| US-6492371-B2 | ADMINISTERING THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND THAT INHIBITS CGMP-SPECIFIC PHOSPHODIESTERASE (PDE5) FOR THERAPY OF PARKINSON'S DISEASE | ROYLANCE H H (US) | 2002-12-10 | — | — | US | disclosed |
| US-6476037-B1 | L-arginine and phosphodiesterase (PDE) inhibitor synergism | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-11-05 | — | — | US | disclosed |
| US-6472434-B1 | VASOACTIVE AGENT IS ADMINISTERED TO THE VAGINA, VULVAR AREA OR URETHRA OF THE INDIVIDUAL UNDERGOING TREATMENT. SUITABLE VASOACTIVE AGENTS ARE VASODILATORS, INCLUDING NATURALLY OCCURRING PROSTAGLANDINS, SYNTHETIC PROSTAGLANDIN DERIVATIVES, | VIVUS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-6469012-B1 | POTENT, SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASES LEAD TO ELEVATED CGMP LEVELS | PFIZER INC | 2002-10-22 | — | — | US | disclosed |
| US-6469016-B1 | VAGINAL, VULVAR AND/OR URETHRAL ADMINISTRATION OF A PHARMACEUTICAL FORMULATION CONTAINING A VASOACTIVE AGENT TO INCREASE VAGINAL LUBRICATION | VIVUS, INC. | 2002-10-22 | — | — | US | disclosed |
| EP-1248623-A2 | TREATMENT OF DIABETIC ULCERS | Pfizer Limited (GB) | 2002-10-16 | — | — | EP | disclosed |
| US-20020119974-A1 | Methods and compositions for treating diseases and conditions of the eye | LATIES ALAN M (US) | 2002-08-29 | — | — | US | disclosed |
| US-20020077274-A1 | Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease | LILLY ICOS L.L.C. | 2002-06-20 | — | — | US | disclosed |
| US-6403597-B1 | PRETREATMENT SEXUAL INTERCOURSE | VIVUS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | VIVUS, INC. | 2002-03-28 | — | — | US | disclosed |
| WO-2002019213-A2 | METHOD FOR TREATMENT OF MIGRAINE USING PDE5 INHIBITORS | LILLY ICOS LLC (US) | 2002-03-07 | — | — | WO | disclosed |
| US-20020006926-A1 | Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease | LILLY ICOS LLC | 2002-01-17 | — | — | US | disclosed |
| US-20020004498-A1 | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | DOHERTY PAUL C (US) | 2002-01-10 | — | — | US | disclosed |
| US-20010055570-A1 | Cyclic guanosine 3',5'-monophosphate phosphodiesterases (cGMP PDEs); using specified pyrazolopyrimidinone or aminoquinazoline derivatives | NAEF RETO (CH) | 2001-12-27 | — | — | US | disclosed |
| US-20010053780-A1 | Daily treatment for erectile dysfunction using a PDE5 inhibitor | LILLY ICOS LLC, A DELAWARE CORPORATION | 2001-12-20 | — | — | US | disclosed |
| US-20010051656-A1 | Co-administration of a prostaglandin and an androgenic agent in the treatment of female sexual dysfunction | PLACE VIRGIL A (US) | 2001-12-13 | — | — | US | disclosed |
| WO-2001078711-A2 | PDE-V INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE | LILLY ICOS, LLC. (US) | 2001-10-25 | — | — | WO | disclosed |
| US-6306841-B1 | NITROVASODILATOR SELECTED FROM SODIUM NITROPRUSSIDE, DIAZENIUM DIOLATE MOLSIDOMINE, LINSIDOMINE CHLORHYDRATE, S-NITROSOTHIOLS, ORGANIC NITRATES, PHARMACOLOGICALLY ACCEPTABLE SALTS, | ASIVI, LLC | 2001-10-23 | — | — | US | disclosed |
| US-6294550-B1 | ADMINISTERING A VASOACTIVE AGENT FROM ERGOTAMINE DRUG | ASIVI, LLC | 2001-09-25 | — | — | US | disclosed |
| WO-2001051042-A2 | TREATMENT OF DIABETIC ULCERS | PFIZER LIMITED (GB) | 2001-07-19 | — | — | WO | disclosed |
| US-6225315-B1 | ADMINISTERING A CGMP PDE INHIBITOR. | PFIZER INC | 2001-05-01 | — | — | US | disclosed |
| US-6200980-B1 | ADMINISTERING PHENYL PURINONE COMPOUND FOR TREATING PRECANCEROUS LEISONS | CELL PATHWAYS, INC. | 2001-03-13 | — | — | US | disclosed |
| US-6200591-B1 | HIGH SPEED, ACCUARCY SUPPLYING THROUGH NOSE | NEW MILLENNIUM PHARMACEUTICAL RESEARCH, INC. | 2001-03-13 | — | — | US | disclosed |
| EP-1074258-A2 | Methods and compositions for treating diseases and conditions of the eye | Pfizer Products Inc. (US) | 2001-02-07 | — | — | EP | disclosed |
| US-6127363-A | FOR TRANSURETHRAL OR TRANSDERMAL ADMINISTRATION OR INTRACAVERNOSAL INJECTION, KITS | VIVUS, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-1022026-A2 | Pharmaceutical compositions for treating nitrate-induced tolerance | Pfizer Limited (GB) | 2000-07-26 | — | — | EP | disclosed |
| US-6037346-A | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| WO-1999066933-A1 | NASAL ADMINISTRATION OF SILDENAFIL FOR THE TREATMENT OF ERECTILE DYSFUNCTION | NEW MILLENNIUM PHARMACEUTICAL RESEARCH, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0951908-A2 | Method of treating impotence due to spinal cord injury | Pfizer Limited (GB) | 1999-10-27 | — | — | EP | disclosed |
| EP-0702555-B1 | PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF IMPOTENCE | PFIZER LTD (GB) | 1998-03-11 | — | — | EP | disclosed |
| EP-0463756-B1 | Pyrazolopyrimidinone antianginal agents | PFIZER LTD (GB) | 1995-04-19 | — | — | EP | disclosed |
| US-5346901-A | Treatment of angina, hypertension, heart failure and atherosclerosis | PFIZER INC. (US) | 1994-09-13 | — | — | US | disclosed |
| US-5250534-A | Inhibitors of cyclic guanosine 3*,5*-monophosphate phosphodiesterase | PFIZER INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0463756-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1992-01-02 | — | — | EP | disclosed |
| EP-0463756-A1 | Pyrazolopyrimidinone antianginal agents | Pfizer Limited (GB) | 1992-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (20 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283260-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | BDKRB2, BDKRB1, PTGIR | PDE5A 302/4885PDE3B 177/4885PDE3A 169/4885 |
| US-20030027824-A1 | Pyrazolopyrimidinones for the treatment of female sexual dysfunction | FSHR, GNRHR, LHCGR | PDE5A 393/4885PDE3B 308/4885PDE3A 268/4885 |
| US-20020006926-A1 | Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease | PDE7A, PDE4A, PDE5A | PDE5A 3/4885PDE3B 9/4885PDE3A 5/4885 |
| US-20030134861-A1 | Transmucosal phosphodiesterase inhibitors for the treatment of erectile dysfunction | PDE5A, PDE3A, PDE3B | PDE5A 1/4885PDE3B 3/4885PDE3A 2/4885 |
| US-20030144296-A1 | Daily treatment for erectile dysfunction using a PDE5 inhibitor | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE3B 4/4885PDE3A 2/4885 |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | PDE5A 3481/4885PDE3B 2328/4885PDE3A 2619/4885 |
| US-20020004498-A1 | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | PDE3A, PDE5A, PDE3B | PDE5A 2/4885PDE3B 3/4885PDE3A 1/4885 |
| US-20070225217-A1 | Methods, compositions, and kits for the treatment of medical conditions | TNF, PYGM, IL6 | PDE5A 376/4885PDE3B 332/4885PDE3A 391/4885 |
| US-20020037828-A1 | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation | PDE5A, PDE3B, PDE3A | PDE5A 1/4885PDE3B 2/4885PDE3A 3/4885 |
| US-20020119974-A1 | Methods and compositions for treating diseases and conditions of the eye | PDE6C, PDE6D, PDE5A | PDE5A 3/4885PDE3B 8/4885PDE3A 6/4885 |
| US-20010053780-A1 | Daily treatment for erectile dysfunction using a PDE5 inhibitor | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE3B 4/4885PDE3A 2/4885 |
| US-20030055070-A1 | Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction | PDE5A, HTR5A, PDE3A | PDE5A 1/4885PDE3B 5/4885PDE3A 3/4885 |
| US-20120046285-A1 | BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | BDKRB2, BDKRB1, PTGIR | PDE5A 302/4885PDE3B 177/4885PDE3A 169/4885 |
| US-20040014761-A1 | Treatment of female sexual dysfunction with phosphodiesterase inhibitors | PDE3A, PDE3B, PDE12 | PDE5A 4/4885PDE3B 2/4885PDE3A 1/4885 |
| US-20060040935-A1 | Method of treating impotence due to spinal cord injury | PDE3A, PDE3B, PDE5A | PDE5A 3/4885PDE3B 2/4885PDE3A 1/4885 |
| US-20060014754-A1 | Methods and compositions for treating diseases and conditions of the eye | PDE6C, PDE6D, PDE6A | PDE5A 5/4885PDE3B 9/4885PDE3A 6/4885 |
| US-20030176442-A1 | Treatment of diabetic ulcers | PDE5A, PDE3B, PDE3A | PDE5A 1/4885PDE3B 2/4885PDE3A 3/4885 |
| US-20150250791-A1 | COMBINING SILDENAFIL WITH CAFFEINE IN AN ORAL DISINTEGRATING DOSAGE FORM | PDE3B, PDE3A, PDE2A | PDE5A 4/4885PDE3B 1/4885PDE3A 2/4885 |
| US-20110009322-A1 | USE OF BRADYKININ AND RELATED B2R AGONISTS TO TREAT OCULAR HYPERTENSION AND GLAUCOMA | BDKRB2, BDKRB1, PTGIR | PDE5A 480/4885PDE3B 236/4885PDE3A 286/4885 |
| US-20020077274-A1 | Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease | PDE7A, PDE4A, PDE5A | PDE5A 3/4885PDE3B 9/4885PDE3A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.